The feed-forward loop between YB-1 and MYC is essential for multiple myeloma cell survival

被引:47
作者
Bommert, K. S. [1 ]
Effenberger, M. [1 ]
Leich, E. [2 ]
Kuespert, M. [3 ]
Murphy, D. [3 ]
Langer, C. [4 ]
Moll, R. [5 ]
Janz, S. [6 ]
Mottok, A. [2 ]
Weissbach, S. [2 ]
Rosenwald, A. [2 ]
Bargou, R. [1 ]
Bommert, K. [1 ]
机构
[1] Univ Hosp Wurzburg, Comprehens Canc Ctr Mainfranken, Dept Internal Med 2, Div Haematol & Med Oncol, D-97078 Wurzburg, Germany
[2] Univ Wurzburg, Inst Pathol, Wurzburg, Germany
[3] Univ Wurzburg, Theodor Boveri Inst, D-97070 Wurzburg, Germany
[4] Univ Ulm, Dept Internal Med 3, D-89069 Ulm, Germany
[5] Univ Giessen & Marburg, Inst Pathol, Marburg, Germany
[6] Univ Iowa, Dept Pathol, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA
关键词
translational control; YBX1; oncogenic circuit; INTERNAL RIBOSOME ENTRY; BOX BINDING-PROTEIN; COLD-SHOCK DOMAIN; C-MYC; TRANSLATIONAL CONTROL; DRUG-RESISTANCE; MESSENGER-RNA; EXPRESSION; GENE; GROWTH;
D O I
10.1038/leu.2012.185
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Y-box binding protein 1 (YB-1) functions as a translational regulator and has been suggested to elevate MYC mRNA translation via an internal ribosome entry segment (IRES) point mutation in multiple myeloma (MM). We show that YB-1-mediated translation of MYC mRNA occurs independently of the reported IRES mutation, as 87 MM patients (n = 88) and all tested human MM cell lines (HMCLs) were negative for the mutation. We show for the first time that positive MYC staining predicts YB-1 co-expression in malignant plasma cells and YB-1/MYC co-expression increases from 30% in medullary to 70% in extramedullary MM. YB-1 knockdown in HMCLs reduced both MYC protein levels and MYC mRNA in the polysomal fraction, providing a mechanism by which YB-1 controls MYC translation. MYC transcription of YB-1 is demonstrated in HMCLs as MYC knockdown resulted in reduced YB-1 protein and mRNA levels. Furthermore, MYC activation in non-malignant mouse embryonic fibroblasts (MEFs) increased YB-1 mRNA, clearly indicating that MYC drives YB-1 transcription. Importantly, perturbation of the MYC/YB-1 oncogenic circuit leads to apoptosis in HMCLs. Here, we demonstrate that these two proteins co-regulate each other via combined transcriptional/translational activity establishing their pivotal role in MM cell survival. We therefore suggest that targeting the YB-1/mRNA interaction provides a new strategy for MM drug development. Leukemia (2013) 27, 441-450; doi:10.1038/leu.2012.185
引用
收藏
页码:441 / 450
页数:10
相关论文
共 36 条
[1]   Novel translational control through an iron-responsive element by interaction of multifunctional protein YB-1 and IRP2 [J].
Ashizuka, M ;
Fukuda, T ;
Nakamura, T ;
Shirasuna, K ;
Iwai, K ;
Izumi, H ;
Kohno, K ;
Kuwano, M ;
Uchiumi, T .
MOLECULAR AND CELLULAR BIOLOGY, 2002, 22 (18) :6375-6383
[2]   Phosphorylation by Akt disables the anti-oncogenic activity of YB-1 [J].
Bader, A. G. ;
Vogt, P. K. .
ONCOGENE, 2008, 27 (08) :1179-1182
[3]   Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression [J].
Bargou, RC ;
Jurchott, K ;
Wagener, C ;
Bergmann, S ;
Metzner, S ;
Bommert, K ;
Mapara, MY ;
Winzer, KJ ;
Dietel, M ;
Dorken, B ;
Royer, HD .
NATURE MEDICINE, 1997, 3 (04) :447-450
[4]   YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification [J].
Bergmann, S ;
Royer-Pokora, B ;
Fietze, E ;
Jürchott, K ;
Hildebrandt, B ;
Trost, D ;
Leenders, F ;
Claude, JC ;
Theuring, F ;
Bargou, R ;
Dietel, M ;
Royer, HD .
CANCER RESEARCH, 2005, 65 (10) :4078-4087
[5]   A mutation in the c-myc-IRES leads to enhanced internal ribosome entry in multiple myeloma:: A novel mechanism of oncogene de-regulation [J].
Chappell, SA ;
LeQuesne, JPC ;
Paulin, FEM ;
deSchoolmeester, ML ;
Stoneley, M ;
Soutar, RL ;
Ralston, SH ;
Helfrich, MH ;
Willis, AE .
ONCOGENE, 2000, 19 (38) :4437-4440
[6]   The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma [J].
Chatterjee, Manik ;
Rancso, Christoph ;
Stuehmer, Thorsten ;
Eckstein, Niels ;
AndruliS, Mindaugas ;
Gerecke, Christian ;
Lorentz, Heike ;
Royer, Hans-Dieter ;
Bargoul, Ralf C. .
BLOOD, 2008, 111 (07) :3714-3722
[7]   Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma [J].
Chng, W-J ;
Huang, G. F. ;
Chung, T. H. ;
Ng, S. B. ;
Gonzalez-Paz, N. ;
Troska-Price, T. ;
Mulligan, G. ;
Chesi, M. ;
Bergsagel, P. L. ;
Fonseca, R. .
LEUKEMIA, 2011, 25 (06) :1026-1035
[8]   Upregulated c-myc expression in multiple myeloma by internal ribosome entry results from increased interactions with and expression of PTB-1 and YB-1 [J].
Cobbold, L. C. ;
Wilson, L. A. ;
Sawicka, K. ;
King, H. A. ;
Kondrashov, A. V. ;
Spriggs, K. A. ;
Bushell, M. ;
Willis, A. E. .
ONCOGENE, 2010, 29 (19) :2884-2891
[9]   Identification of internal ribosome entry segment (IRES)-trans-acting factors for the Myc family of IRESs [J].
Cobbold, Laura C. ;
Spriggs, Keith A. ;
Haines, Stephen J. ;
Dobbyn, Helen C. ;
Hayes, Christopher ;
de Moor, Cornelia H. ;
Lilley, Kathryn S. ;
Bushell, Martin ;
Willis, Anne E. .
MOLECULAR AND CELLULAR BIOLOGY, 2008, 28 (01) :40-49
[10]   BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc [J].
Delmore, Jake E. ;
Issa, Ghayas C. ;
Lemieux, Madeleine E. ;
Rahl, Peter B. ;
Shi, Junwei ;
Jacobs, Hannah M. ;
Kastritis, Efstathios ;
Gilpatrick, Timothy ;
Paranal, Ronald M. ;
Qi, Jun ;
Chesi, Marta ;
Schinzel, Anna C. ;
McKeown, Michael R. ;
Heffernan, Timothy P. ;
Vakoc, Christopher R. ;
Bergsagel, P. Leif ;
Ghobrial, Irene M. ;
Richardson, Paul G. ;
Young, Richard A. ;
Hahn, William C. ;
Anderson, Kenneth C. ;
Kung, Andrew L. ;
Bradner, James E. ;
Mitsiades, Constantine S. .
CELL, 2011, 146 (06) :903-916